Insulet targets 16%-20% U.S. Omnipod growth for 2025 with expanded type 2 diabetes market reach
Source: SeekingAlpha
2025-02-20 23:37:39 ET
More on Insulet
- Insulet Corporation (PODD) Q4 2024 Earnings Call Transcript
- Insulet Non-GAAP EPS of $1.15 beats by $0.13, revenue of $597.5M beats by $15.48M
- v
- Seeking Alpha’s Quant Rating on Insulet
- Historical earnings data for Insulet
Read the full article on Seeking Alpha
For further details see:
Insulet targets 16%-20% U.S. Omnipod growth for 2025 with expanded type 2 diabetes market reach
Insulet Corporation
NASDAQ: PODD
PODD Trading
-0.35% G/L:
$209.755 Last:
251,506 Volume:
$205.86 Open:
PODD Latest News
July 08, 2025 06:00:00 am
Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025
June 19, 2025 06:00:00 am
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions
June 10, 2025 08:30:00 am
Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users
PODD Stock Data
$17,809,372,432
69,643,429
0.03%
360
N/A
Medical Equipment & Supplies
Healthcare
US
Acton
